Posts by author
Janet Fricker
Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib plus the BCL2 inhibitor venetoclax (with or without the CD20 inhibitor obinutuzumab), delivered as fixed-duration therapies, significantly improved progression free survival in comparison with standard-of-care chemotherapy in previously untreated patients…
New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations
Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent risk-reducing bilateral mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of death than those not undergoing these procedures. The study, presented at the 2024 San…
Gut microbiota influence effectiveness of tamoxifen in breast cancer
Variations in the microbiota of the human gut impact on the pharmacokinetics of tamoxifen in the blood and consequently on the effectiveness of breast cancer prevention. The study, published in the journal mBio, 25 November, showed that the presence of…
Radiotherapy prior to immunotherapy is the best treatment sequence for melanoma related brain metastases
Patients with melanoma related brain metastases achieve reduced risk of progression and better overall survival if they receive radiotherapy before immunotherapy as opposed to the other way round. The meta-analysis study, abstract RADT-04, presented at the Society of Neuro Oncology…
Study helps solve the puzzle of checkpoint inhibitor myocarditis
The immune reaction that occurs in the hearts of patients taking checkpoint inhibitors who develop immune checkpoint myocarditis may be distinct from the immune responses occurring in the tumours of these patients. The study, published in in Nature, 6 November,…
Smoking cessation fundamental to first-line cancer care
Cancer patients who enter a smoking cessation programme within six months of receiving a diagnosis, and quit within three months after programme entry, experience a 26% reduction in mortality versus those who continue smoking. The study, published in in JAMA…
Large-scale whole genome sequencing identifies six new cancer susceptibility/ resistance genes
Six previously unreported genes have been revealed to harbour rare germline mutations that associate with cancer risk. The study, published in Nature Genetics, 29 October, identified 34 genes associated with cancer risk, including four novel genes associated with increased cancer…
Lessons in nature: knowledge of exceptional animals could help tackle human cancers
Cancer prevalence across vertebrate species increases with higher adult mass and decreases with longer gestation periods. The study, published in Cancer Discovery, October 24, has identified more than 90 different species of animals (including the common dolphin, common porpoise and…
Breast cancer treatments may accelerate ageing
Breast cancer treatments activate genes associated with biological ageing. The study, published in the Journal of the National Cancer Institute, 8 October, suggests that chemotherapy, radiation, and surgery all lead to statistically significant increases in cellular senescence and DNA damage…
Targeting a circulating cytokine offers new hope in cancer cachexia
Among patients with cancer cachexia and elevated levels of the cytokine GDF-15, inhibiting GDF-15 with ponsegromab resulted in increased weight gain. The study, published in the New England Journal of Medicine, 14 September, showed that in comparison to placebo, patients taking ponsegromab…